For 2017, $JNJ stated that even without the impact of Remicade biosimilars, the growth rate in pharma business is going to be slower than it was in 2016. The company expects medical devices and consumer businesses to accelerate the growth in 2017 over 2016.
$KMB said it will have some carryover price drag in places like
China but it might get some additional positive price increases in markets like
Brazil and Argentina. In markets like the UK, $KMB will try to take some small
positive price increases but it does not expect this to drive 2017. There is limited
opportunity for price increases.
$ORIT reported a drop in 2Q17 earnings due to last year's profits on the sale of investments in real estate joint ventures. Net income fell to $11.4MM or $0.26 per share from $16.4MM or $0.38 per share last year. Net interest income rose to $26.23MM from $25.29MM, while total other income dropped to $1.18MM from $27.48MM.
$DHI expects to generate $300-500MM in cash flow in 2017, of which it will use $350MM to pay down debt while continuing to reinvest in the business. In addition, the company said it expects to pay $150MM in dividends in 2017.
$JNJ, which acquired $ABT’s subsidiary Abbott Medical Optics in Sept. 2016 for $4.325Bil, said that it would close this acquisition in 1Q17. The company has now completed approx. 75% of its $10Bil share repurchase program and expects to complete this program during 1H17.